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Conclusions.– In PD, 8 weeks of intensive physical therapy improve movement
scaling only on the more affected side. These findings suggest an enhanced
dopaminergic input in the more affected nigrostriatal pathways after intensive
motor training in PD.
http://dx.doi.org/10.1016/j.rehab.2014.03.1211
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Objective.– Hypometry and bradykinesia alter mobility in Parkinson’s disease
(PD), making standing up from the floor difficult. We evaluated the effects of a
standardized, intensive home rehabilitation program.
Methods.– Twenty-one PD patients (age 68 ± 10) were evaluated using the
Global Mobility Test (GMT, involving filming and timing of the task of standing
up from the floor) in the practically defined OFF-state before and after an 8-week
intensive home therapy program involving aerobic and strengthening exercises,
1 hour 3 times a week for 8 weeks, and re-assessed 3 months after the end of the
program (n = 10).
Results.– Time to stand up from the floor was improved at 8 weeks (D1,
37.8 ± 7.4 s; D60, 26.9 ± 4.6 s, P < 0.05, Wilcoxon). The most improved part
was the getting up from “knight position” (D1, 12.3 ± 4.1 s, D60, 5.2 ± 1.3 s,
P < 0.01). Improvements persisted at D150 (n = 10; D1 39.2 ± 9.9 s; D60
25.6 ± 5.1 s; D150 19.6 ± 4.7 s, P < 0.05).
Conclusion.– An 8-week intensive home therapy program in PD involving
appears to produce functional effects comparable to those of dopaminergic drugs.
This study also suggests persistence of these effects 3 months after the end of
the program, probably as patients retained the teaching of exercises that they
continued to practice at home.
http://dx.doi.org/10.1016/j.rehab.2014.03.1212
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Objective.– Our aim is to verify the validity of neurocognitive rehabilitation
grounding on the observation of perceptive as well as motor disorders in Parkin-
son’s disease (PD).
Methods.– A 49-year-old woman with a clinical history of PD since 2001 was
enrolled. She attended twenty sessions (1 hour each) of neuro-cognitive rehabil-
itation, twice a week over 3 months. Outcomes included self-confidence in gait
(primary), the course of disease and pain as a freezing’s prodrome (secondary),
Unified Parkinson’s Disease Rating Scale, Tinetti Balance and Gait Evaluation,
Visual Analogue Scale, at the beginning (T0) and at the end of the treatment
(T1), with a follow-up 3 months after the end (T2).
Results.– A decrease in the risk of falling, both when standing and during gait,
was observed between T0, T1 and T2.
Discussion.– Neuro-cognitive rehabilitation may be considered effective in peo-
ple with PD.
Further reading
Nieuwboer A, Giladi N. Characterizing freezing of gait in Parkinson’s disease:
models of an episodic phenomenon. Mov Disord 2013;28(11):1509–19.
http://dx.doi.org/10.1016/j.rehab.2014.03.1213
P402-e
tDCS to treat freezing of gait in Parkinson’s
disease: A single-case design
E. Andrenelli ∗, C. Orni , L. Provinciali , M.G. Ceravolo ,
M. Capecci
Department of Experimental and Clinical Medicine, Politecnica delle Marche
University, Ancona, Italy
∗Corresponding author.
Keywords: Parkinson’s disease; Transcranial direct current stimulation;
Freezing of gait
Objective.– We investigated the effects of transcranial Direct Current Stim-
ulation (tDCS) in a 50-year-old subject suffering from Parkinson’s disease,
complicated by drug-resistant freezing of gait (FOG).
Methods.– Three sessions of 2.0 mA cathodal tDCS were carried out, 30 days
apart from each other. In the first session, tDCS was delivered to the prefrontal
cortex, in the second one to the parietal cortex, while in the last, a sham-
stimulation of the prefrontal cortex was done. Right and left hemispheres were
separately stimulated in each session. Outcomes included performance time
and number of FOG events during the Timed Up-and Go test, UPRDS-III and
cognitive performances.
Results.– Prefrontal stimulation abolished FOG events, though providing a lower
effect on TUG time than parietal stimulation. Parietal cortex tDCS improved
single-TUG time up to 34%, with minor impact on dual-task time, and negligible
effect on FOG events. UPDRS-III decreased after both prefrontal and parietal
stimulation (by 31% and 36% respectively). Cognitive task scores increased
after prefrontal stimulation, though not after parietal stimulation. No changes in
motor or cognitive outcomes resulted from sham stimulation.
Discussion.– Prefrontal cortex tDCS may improve specific motor and cognitive
performances in Parkinson’s disease.
http://dx.doi.org/10.1016/j.rehab.2014.03.1214
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Objective.– We compared the efficacy and safety of botulinum toxin type A
(BTX-A) and B (BTX-B) in Parkinson’s disease (PD) patients suffering from
disabling drooling.
Methods.– Forty-four subjects (PD duration: 14.8 + 6.6 years) with severe drool-
ing were randomized into two groups, either receiving BTX-A (50 U Botox in
each side) or BTX-B injections (2000 U Neurobloc in each side) in the parotid
glands. Outcome measures included visual analogue scale for the assessment of
drooling-related family (VAS-FD) and social (VAS-SD) distress, the Sialorrhea
Scoring Scale (SSS), UPDRS-ADL scores of speech and dysphagia items to
appraise side effects, immediately before treatment and after one month.
Results.– At one month, all subjects reported an improvement of VAS-FD (time
effect: F = 82.7, P < .0001) and VAS-SD (F = 74.5, P < .0001) following drooling
reduction; the SSS score improved by 60% (F = 197, P < .0001). A greater impact
of BTX-B was appreciated for both the VAS-SD score (time × treatment effect:
F = 8.1, P = .005) and the SSS score (F = 17.2; P < .0001). Neither swallowing
ability nor speech worsened after treatment.
